{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-25-000002","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.970018+00:00","generated_at":"2026-05-28T10:40:08.293204+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AbbVie reports $1.574B Q4 IPR&D charge, cuts adjusted EPS guidance by $0.88","bullets":["Expected Q4 2024 acquired IPR&D and milestones expense of $1,574M pre-tax, $0.88 per share impact.","Adjusted diluted EPS guidance for Q4 2024 revised to $2.06-$2.10 (from $2.94-$2.98).","Full-year 2024 adjusted diluted EPS guidance revised to $10.02-$10.06 (from $10.90-$10.94).","Previous guidance excluded Q4 IPR&D expense; company does not forecast such expenses.","Q4 2024 results not finalized; subject to closing procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-25-000002","json":"https://secwatch.observer/filing/0001551152-25-000002.json","markdown":"https://secwatch.observer/filing/0001551152-25-000002.md","text":"https://secwatch.observer/filing/0001551152-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000002/0001551152-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000002/abbv-20250106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T10:40:08.293204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}